| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
Dopamine receptor blocking drugs, commonly used in the treatment of involuntary movements, may cause potentially serious adverse effects, including tardive dyskinesia. Tardive dyskinesia has not been reported with tetrabenazine, a dopamine-depleting drug. We report a follow-up in 217 patients treated with tetrabenazine for about 18 months (range, 1 to 80). The response was rated on a scale of 0 to 5 (1 = marked improvement, 4 = no response, 5 = worsening). The mean effect from tetrabenazine was rated as follows: 2.3 in 44 patients with tardive dyskinesia, 2.6 in 15 with tardive dystonia, 2.6 in 10 with Huntington's disease, 2.7 in 17 with Gilles de la Tourette's syndrome, 2.8 in 19 with generalized dystonia, 2.8 in 57 with Meige's syndrome, and 3.4 in 25 with other focal dystonias. Twenty-two patients with a variety of unusual movement disorders had a mean effect of 2.9. Parkinsonism occurred as a side effect in 53 patients, sedation in 28, depression in 23, anxiety in 16, insomnia in 11, and akathisia in 10. The choreatic movement disorders are most amenable to tetrabenazine therapy, but tardive and idiopathic dystonia may also be responsive. Tetrabenazine is an effective and relatively safe drug for a variety of hyperkinetic movement disorders.
Address correspondence and reprint requests to Dr. Jankovic, Director, Parkinson's Disease and Movement Disorder Center, Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030.
Presented in part at the thirty-ninth annual meeting of the American Academy of Neurology, New York, NY, April 1987.
Received April 30, 1987. Accepted for publication in final form June 9, 1987.
This article has been cited by other articles:
|
|
 |
|
  K. Dashtipour, M. Barahimi, and S. Karkar Cervical Dystonia Journal of Pharmacy Practice, December 1, 2007; 20(6): 449 - 457. [Abstract] [PDF]
|
|
|
|
 |
|
 Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial Neurology, February 14, 2006; 66(3): 366 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K A Josephs, M W Van Gerpen, and J A Van Gerpen Adult onset Niemann-Pick disease type C presenting with psychosis J. Neurol. Neurosurg. Psychiatry, April 1, 2003; 74(4): 528 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Sanger Pathophysiology of Pediatric Movement Disorders J Child Neurol, January 1, 2003; 18(1_suppl): S9 - S24. [Abstract] [PDF]
|
|
|
|
|
|
R. Saunders-Pullman, J. Shriberg, G. Heiman, D. Raymond, K. Wendt, P. Kramer, K. Schilling, R. Kurlan, C. Klein, L. J. Ozelius, et al. Myoclonus dystonia: Possible association with obsessive-compulsive disorder and alcohol dependence Neurology, January 22, 2002; 58(2): 242 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Robertson Tourette syndrome, associated conditions and the complexities of treatment Brain, March 1, 2000; 123(3): 425 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Ondo, P. A. Hanna, and J. Jankovic Tetrabenazine Treatment for Tardive Dyskinesia: Assessment by Randomized Videotape Protocol Am J Psychiatry, August 1, 1999; 156(8): 1279 - 1281. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Green, C. Proch, and S. E. Gara Review Article : The Changing Face of Cerebral Palsy: A Review of the Disorder and Its Treatment Neurorehabil Neural Repair, January 1, 1997; 11(4): 245 - 253. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Pranzatelli Oral Pharmacotherapy for the Movement Disorders of Cerebral Palsy J Child Neurol, November 1, 1996; 11(1_suppl): S13 - S22. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Al Jishi, M.Z. Al Kawi, K. El Ramahi, and S. Omer Hemichorea in systemic lupus erythematosus: significance of MRI findings Lupus, August 1, 1995; 4(4): 321 - 323. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
